Shao et al., Clinical advancement of patients infected with SARS-CoV-2 Omicron variant in Shanghai, China, medRxiv, doi:10.1101/2022.07.03.22277169 (Preprint)
Retrospective 17 paxlovid and 114 lianhuaqingwen patients in China, showing faster viral clearance with paxlovid.[Hoertel] find that over 50% of patients that died had a contraindication for the use of Paxlovid. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details.
Shao et al., 6 Jul 2022, retrospective, China, preprint, median age 52.0, 12 authors, study period 6 April, 2022 - 11 May, 2022, this trial compares with another treatment - results may be better when compared to placebo.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2022.07.03.22277169; this version posted July 6, 2022. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.
Title: Clinical advancement of patients infected with SARS-CoV-2
Omicron variant in Shanghai, China
Jiasheng Shao 1*, Rong Fan 2*, Tiejun Zhang3*, Catherine Lee4, Xuyuan Huang5,
Fei Wang6, Haiying Liang7, Ye Jin7, Ying Jiang7, Yanhua Gu8, Jianrong Hu7#,
Gang Huang9#
、 Department of Infectious Diseases and Immunology, Jiading District Central
1
Hospital, Shanghai University of Medicine and Health Sciences, Shanghai
201899, China
、 Genomics, Center for Molecular and Cellular Bioengineering, Biotechnology
2
Center, Technische Universität Dresden 01307, Germany
、 Department of Epidemiology, School of Public Health, Fudan University,
3
Shanghai 200032, China
、 College of Public Health, University of Georgia, Athens, GA 30602, USA
5、 Department of Urology, Renji Hospital, Shanghai Jiaotong University,
4
Shanghai 200127, China
、 Department of Intensive Care Unit, Jiading District Central Hospital, Shanghai
6
201899, China
、 Department of Respiratory Medicine, Jiading District Central Hospital,
7
Shanghai 201899, China
、 Department of Nursing, Jiading District Central Hospital, Shanghai 201899,
8
China
、 Shanghai Key Laboratory of Molecular Imaging, Shanghai University of
9
Medicine and Health Sciences, Shanghai 201318, China
1
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2022.07.03.22277169; this version posted July 6, 2022. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.
Running title: Omicron variant clinical advancement in Shanghai
#
Corresponding Authors:
Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine
and Health Sciences, Shanghai 201318, China,
E-mail address: huanggang@sumhs.edu.cn (G. Huang), Tel: 86-021-65881330
Department of Respiratory Medicine, Jiading District Central Hospital, Shanghai
201899, China
E-mail address: hujianrong@jdhospital.com (J. Hu), Tel: 86-021-67073583
*These authors contributed equally to this work.
Keyword: SARS-CoV-2; Omicron variant; Vaccination; PCR conversion;
Paxlovid
ABSTRACT
Background
Studies on the Omicron variant infection have generally been restricted to
descriptions of its initial clinical and epidemiological characteristics. We
investigated the timeline-related advancement in individuals with Omicron variant.
Methods
We conducted a retrospective, single-centered study including 226
laboratory-confirmed cases with Omicron variant between April 6th and May 11th,
2022 in Shanghai, China. Final date of follow-up was May 30, 2022.
Results
Among 226 enrolled patients, the median age was 52 years old, and 118 (52.2%)
were female. The duration from onset of symptoms to hospitalization was 3 days
(interquartile range [IQR]: 2-4 days) for symptomatic patients. Cough occurred in
2
medRxiv preprint doi: https://doi.org/10.1101/2022.07.03.22277169; this version posted July 6, 2022. The copyright holder..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.